Lifeward Ltd.

Lifeward Ltd. is a medical device company that designs, develops, and commercializes solutions for physical rehabilitation and recovery, focusing on enhancing mobility and wellness for individuals with physical and neurological conditions. The company's mission is to relentlessly drive innovation to transform the lives of individuals with physical limitations or disabilities, empowering them to pursue their ambitions. Lifeward is headquartered in Yokneam Illit, Israel, with significant operations in Marlborough, Massachusetts, USA, and Berlin, Germany.

Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. These technologies provide gait training and mobility assistance for a range of conditions, including spinal cord injury, stroke, multiple sclerosis, brain injury, and orthopedic/sports medicine rehabilitation. The company supports both clinical settings and home/community use, offering comprehensive customer support and technical service for its products.

In recent developments, Lifeward successfully closed a strategic partnership with Oramed in March 2026, acquiring Oramed's Protein Oral Delivery (POD™) technology and securing up to $47 million in funding to diversify its biomedical innovation efforts. Mark Grant assumed the role of President and CEO in June 2025. The company also achieved CE Mark approval for its ReWalk 7 Personal Exoskeleton in September 2025 and expanded Medicare Advantage coverage for the ReWalk Personal Exoskeleton to include major insurers like Aetna, Humana, and United Healthcare in February 2026. Lifeward continues to expand its offerings, including the acquisition of AI-enabled upper body exoskeleton technology for stroke survivors in February 2026, solidifying its position as a global leader in rehabilitation technology.